Sullivan J L, Byron K S, Brewster F E, Sakamoto K, Shaw J E, Pagano J S
Am J Med. 1982 Jul 20;73(1A):262-6. doi: 10.1016/0002-9343(82)90102-4.
Two pediatric patients with life-threatening Epstein-Barr virus infections were studied immunologically and treated with acyclovir [9-(2-hydroxyethoxymethyl) guanine]. The patient with chronic active Epstein-Barr virus infection who experienced massive hepatosplenomegaly, pancytopenia, and failure to thrive demonstrated abnormalities of T and B lymphocytes. A second patient, with the X-linked lymphoproliferative syndrome, experienced a rapidly fatal course of acute Epstein-Barr virus infection which typifies this yet undefined immunodeficiency to Epstein-Barr virus. In each case, objective evidence for clinical improvement or antiviral effect of acyclovir treatment was not apparent. Abnormally productive Epstein-Barr virus infections did not appear to play a major role in the clinical syndromes observed. Current studies are focused on treatment of immunologically normal patients with early complicated Epstein-Barr virus infection.
对两名患有危及生命的爱泼斯坦-巴尔病毒感染的儿科患者进行了免疫学研究，并用阿昔洛韦[9-(2-羟乙氧甲基)鸟嘌呤]进行治疗。患有慢性活动性爱泼斯坦-巴尔病毒感染的患者出现了巨大肝脾肿大、全血细胞减少和发育不良，表现出T和B淋巴细胞异常。第二名患有X连锁淋巴增殖综合征的患者经历了急性爱泼斯坦-巴尔病毒感染的快速致命病程，这是这种尚未明确的对爱泼斯坦-巴尔病毒免疫缺陷的典型表现。在每种情况下，阿昔洛韦治疗的临床改善或抗病毒效果的客观证据并不明显。异常活跃的爱泼斯坦-巴尔病毒感染似乎在观察到的临床综合征中不起主要作用。目前的研究集中在治疗患有早期复杂爱泼斯坦-巴尔病毒感染的免疫正常患者。
